TCRX
USDTScan Therapeutics Inc. Common Stock
$1.120-0.050 (-4.274%)
Real-time Price
Healthcare
Biotechnology
United States
Price Chart
Loading Chart...
Key Metrics
Market Metrics
Open
$1.170
High
$1.250
Low
$1.080
Volume
0.81M
Company Fundamentals
Market Cap
63.6M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.51M
Exchange
NGM
Currency
USD
52-Week Range
Low $1.02Current $1.120High $6.225
Related News
Analyst Upgrades
BTIG Downgrades TScan Therapeutics to Neutral
BTIG analyst Justin Zelin downgrades TScan Therapeutics from Buy to Neutral.
View more
Analyst Upgrades
Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
Needham analyst Gil Blum maintains TScan Therapeutics with a Buy and lowers the price target from $9 to $6.
View more
GlobeNewswire
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development;
View more
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.